Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium is a synthetic small molecule belonging to the class of phenanthrolines and phenanthrolinium salts. It is an aromatic polycyclic compound with the chemical formula C17H19N2 and a molecular weight of approximately 251.35 g/mol[2][4]. The compound has been studied as an experimental agent and is known to act as an inhibitor of methionine aminopeptidase 2 (METAP2), an enzyme involved in cotranslational removal of N-terminal methionine from nascent proteins[1]. Its primary mechanism involves inhibition of METAP2 activity in human cells. There are no approved therapeutic indications or marketed formulations for this compound; it remains primarily a research tool.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,5,6,8-tetramethyl-N-methyl phenanthrolinium.